semaglutide cvd cardiovascular outcomes align more closely with attained dose than achieved weight loss 🚨 Breaking News: Real-World Data

Patients starting on semaglutide should undergo baseline and regular monitoring, including blood work, to ensure safety and effectiveness, with a focus on re...

Explore GLP-1 for medical weight loss

The Medicare GLP-1 Bridge starts July 1 with $50 weight loss drugs

It has been an exciting summer for our new GLP-1 weight loss medications, Wegovy (semaglutide) and Zepbound (tirzepatide)

Listing is for the storage case only

In most major obesity trials, GLP-1 therapy was: Escalated to high or maximum tolerated doses Stopped abruptly, not down-titrated Followed by little or no continuation of structured lifestyle support In the STEP-1 extension trial (semaglutide 2.4 mg), participants who discontinued therapy regained approximately two-thirds of their prior weight loss over the following year